MK-2894

MK-2894 is a potent, selective, orally active and high affinity (Ki=0.56 nM) full antagonist against E prostanoid receptor 4 (EP4 receptor) (IC50=2.5 nM) . MK-2894 possesses potent anti-inflammatory activity in animal models of pain/inflammation and can be used for the research of arthritis[1][2].

Product Specifications

CAS Number

[1006036-87-8]

UNSPSC

12352005

Target

Prostaglandin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Endocrinology

Assay Protocol

https://www.medchemexpress.com/MK-2894.html

Concentration

10mM

Purity

99.31

Solubility

DMSO : ≥ 50 mg/mL

Smiles

O=C(O)C1=CC=C(C2(NC(C3=C(C)SC(C)=C3CC4=CC=C(C(F)(F)F)C=C4)=O)CC2)C=C1

Molecular Formula

C25H22F3NO3S

Molecular Weight

473.51

References & Citations

[1]Blouin M, et al. The discovery of 4-{1-[ ({2,5-dimethyl-4-[4- (trifluoromethyl) benzyl]-3-thienyl}carbonyl) amino]cyclopropyl}benzoic acid (MK-2894), a potent and selective prostaglandin E2 subtype 4 receptor antagonist. J Med Chem. 2010 Mar 11;53 (5) :2227-38.|[2]Tijana Markovič, et al. Structural features of subtype-selective EP receptor modulators. Drug Discov Today. 2017 Jan;22 (1) :57-71.